Abstract 1596P
Background
Palliative care has shown a positive economic impact in oncology. However, research on its financial viability in oncology, especially in developing countries, is lacking. This study estimates hospitalization costs for cancer patients in the southeast region of Brazil.
Methods
We used a retrospective analysis of electronic medical records for cancer patients treated at a Cancer Center in the southeast region of Brazil. Inclusion criteria were adult patients with any type of cancer who had died at a hospital setting between January 2022 and March 2023. Patients were divided into two groups: those who received outpatient palliative care (OPCT) and those who did not receive any OPCT. Based on the available clinical outcomes of the sample, data was collected on the hospital admission date, length of stay until death, and the type of accommodation until death [admission at intensive care unit (ICU) versus general ward]. To estimate the costs, we used real-world data from private hospitals in the southeast region, measuring the general amounts spent on daily hospitalization and ICU stays, and their respective lengths of stay, without reference to any specific patient or procedures. We performed univariate comparisons using Linear Regression.
Results
Out of the 72 patients with cancer, 29 were followed by the OPCT team, while 43 were not. The average cost of hospitalization for patients who did not receive the OPCT was found to be R$ 20,000.00 (€ 3,651.00; SD = 9.19) higher than those who received OPCT (p = 0.03). We observed that patients who were admitted to the ICU had hospitalization cost, on average, R$ 17,800.00 (€ 3,249.00; SD = 9.61) more than those who stayed in general ward (p = 0.06).
Conclusions
Our study highlights the economic benefits of providing OPCT in a developing country. Based on this analysis, OPCT can reduce healthcare costs by decreasing the length of hospital stay and preventing unnecessary ICU admissions. Our study suggest that policymakers and healthcare providers should prioritize the provision of OPCT in Brazil, and this type of support should be considered as an essential component of end-of-life care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Oncoclinicas.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05